PTC
PVLA icon

Private Trust Company’s Palvella Therapeutics PVLA Stock Holding History

Private Trust Company’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.64K Hold
50
– – ﹤0.01% 2167
2026
Q1 		$6.23K Buy
50
+12
+32% +$1.25K ﹤0.01% 2136
2025
Q4 		$3.98K Sell
38
-13
-25% -$1.11K ﹤0.01% 2218
2025
Q3 		$3.2K Buy
+51
New +$2.27K ﹤0.01% 2266

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Frontier Capital Management
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Private Trust Company's PVLA Position: Q2 2026 in Review

Private Trust Company held its Palvella Therapeutics (PVLA) position steady in Q2 2026 at 50 shares worth $7.64K. The position accounts for ﹤0.01% of the portfolio, ranked #2167.

Private Trust Company first reported a position in PVLA in Q3 2025 and has held it in 4 quarters since. 196 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Private Trust Company held 50 shares of Palvella Therapeutics worth $7.64K as of Q2 2026.
  • Private Trust Company left its Palvella Therapeutics share count unchanged in Q2 2026.
  • Palvella Therapeutics made up ﹤0.01% of Private Trust Company's portfolio in Q2 2026, its #2167 holding.
  • Private Trust Company first reported a position in Palvella Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 196 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Private Trust Company's 13F filing for Q2 2026, filed 28 Jul 2026.